1662 results for "LSD"
IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?
Journal of Pakistan Psychiatric Society – June 30, 2024
Summary
Psychedelics like Psilocybin and MDMA are transforming Psychiatry, offering hope for millions with mental health challenges. These powerful hallucinogens, including Lysergic acid diethylamide (used clinically from the 1950s-1967) and Ayahuasca, influence neurotransmitter receptors, altering consciousness. Clinical psychology and drug studies reveal their potential to disrupt pathological brain activity, promoting neuroplasticity. Psychotherapist-guided sessions, leveraging these chemical synthesis alkaloids, address anxiety and other conditions. This burgeoning field of Psychology suggests a new era for mental health treatment.
Abstract
Psychedelics, substances known to alter perception, mood, and consciousness, have been used across various cultures for centuries, often in religio...
Historical overview
OpenAlex – March 01, 2023
Summary
Human history with Psilocybin and Lysergic acid diethylamide is profound. Indigenous cultures used these hallucinogens for millennia, an ethnology now informing modern understanding. Albert Hofmann synthesized Lysergic acid diethylamide in the 1940s; Psilocybin gained notice in the 1950s, sparking cultural fascination, impacting art and art history. After 1970s drug laws, a 1990s scientific Renaissance began. Psychedelics and Drug Studies now explore their potential, much like a MAGIC telescope explores the cosmos, revealing new perspectives on this complex history.
Abstract
Abstract Humans have a long and complicated history with psychedelic compounds. Originally discovered as a component of certain plants and fungi, t...
Chapter 51. Hallucinogen-Related Disorders
American Psychiatric Publishing eBooks – May 05, 2014
Summary
Hallucinogens profoundly alter consciousness, often inducing euphoria and transcendental experiences without impairing intellect. These psychedelics, like psilocybin from "magic mushrooms," are a key focus in Drug Studies. Plant-based Medicinal Research investigates their natural origins, while Biochemical Analysis and Sensing Techniques illuminate their impact on psychology and psychiatry. Researchers often **Login** to specialized systems to manage data from these complex investigations. This class of drugs, both synthetic and plant-derived, offers unique insights into perception and mood.
Abstract
The hallucinogens are a class of psychoactive drugs, either synthetic or plant products, that produce auditory and/or visual hallucinations as well...
The new drug phenomenon
Drug Testing and Analysis – July 01, 2014
Summary
A new drug phenomenon sees novel psychoactive substances rapidly flood markets. Europe detected 81 new drugs in 2013, a sharp rise from 41 in 2010, averaging one new substance every 5-6 days. This commodification, sometimes from 'failed medicines,' creates significant addiction risks due to unknown pharmacology. Forensic toxicology and drug analysis face immense challenges. The political science of control struggles against this tide, raising engineering ethics concerns about substances influencing neurotransmitter receptors, often explored in psychedelics and drug studies.
Abstract
This special issue provides a multidisciplinary snapshot of recent developments of the broader, arguably phenomenal, changes to the drug market tha...
Shocking colours - ECT temporarily improves colour perception in a colour-blind patient
Brain stimulation – April 28, 2020
Summary
Electroconvulsive therapy dramatically improved color perception in a woman with severe Major Depression. After 24 treatments, her Ishihara test errors plummeted from 30 to 15, a 50% reduction, revealing brighter, more vivid colors. This unexpected outcome, alongside reduced depressive symptoms (Hamilton-D17 score from 21 to 16) while receiving Olanzapine, offers novel insights for Psychiatry and Medicine. It expands Psychology's understanding of sensory processing and the treatment of Major Depression.
Abstract
Electroconvulsive therapy (ECT) is often the last resort in medically treatment-resistant patients. The mechanisms of its efficacy are still somewh...
THE THERAPEUTIC POTENTIAL OF PSYCHEDELICS FOR MENTAL HEALTH DISORDERS: A REVIEW OF CURRENT EVIDENCE
PARIPEX INDIAN JOURNAL OF RESEARCH – May 15, 2023
Summary
Psychoactive substances like psilocybin, MDMA, and Ayahuasca show groundbreaking potential for mental health. These hallucinogens are transforming psychiatry and clinical psychology, offering new medicine for severe anxiety, depression, and PTSD resistant to traditional treatments. Research in Psychedelics and Drug Studies highlights their effectiveness, suggesting how their chemical synthesis and alkaloid nature influence behavior through neurotransmitter receptors. Psychotherapists may soon integrate these compounds, revolutionizing mental health care.
Abstract
The purpose of this review article is to give a summary of the literature on the use of psychedelic drugs, such as psilocybin, LSD, ayahuasca, and ...
Plant Medicine Healing! Discovering the Roots of Psychedelic-Assisted Therapy in Mental Health
Advances in Research – January 30, 2023
Summary
Over 700 million individuals globally suffer from mental illness, highlighting the urgent need for new medicine. Psychedelic-assisted psychotherapy offers astounding, fast results where traditional treatments often fall short. Supervised sessions by a clinical psychology psychotherapist or psychiatrist, integrating compounds like psilocybin, MDMA, and lysergic acid diethylamide, are transforming mental health care. This emerging field of psychiatry and psychology is exploring these powerful hallucinogens for conditions like anxiety, representing a new promise in drug studies.
Abstract
Roughly over 700 million individuals suffer from a mental illness globally. In the United States alone, over 45 million individuals are afflicted w...
Knowledge, perceptions, and use of psychedelics for mental health among autistic adults: An online survey
PLOS mental health. – December 26, 2025
Summary
Autistic adults show strong interest in psychedelics for mental health support. A computer-assisted web interviewing survey of 261 autistic participants found 77.8% willing to try psychedelics like psilocybin for conditions such as anxiety, often addressed in clinical psychology. Remarkably, 69.7% reported past use, with higher doses correlating with lasting mental health improvements. Descriptive statistics underscore the need for inclusive psychiatry and mental health services, acknowledging autistic individuals' distinct needs compared to neurotypical populations in psychedelics and drug studies.
Abstract
Psychedelics such as psilocybin, LSD, and MDMA have shown promise in treating mental health conditions (e.g., depression, post-traumatic stress dis...
Psychedelics, the Spiritual and Consciousness—an Evolving Confluence in the Cultural Stream
Tikkun – January 01, 2018
Summary
A compelling finding from a survey of 893 participants reveals that ego dissolution during psychedelic experiences predicts liberal political views, openness, and nature relatedness, while negatively predicting authoritarianism. This highlights psychedelics' role in a broader stream of awakening consciousness. Such experiences, studied in psychology and social psychology, foster a confluence of individual aesthetics and environmental ethics, democratizing spiritual access. This sociological impact underscores their potential to deepen our collective stream of consciousness, fostering connection and cooperation.
Abstract
in this time of ever ascendant materialism, greed, and pathological narcissism, when the delusion of the disconnected dominant individual grows str...
Hair Analysis for Drugs of Abuse. X. Effect of Physicochemical Properties of Drugs on the Incorporation Rates into Hair.
Biological and Pharmaceutical Bulletin – January 01, 1995
Summary
Cocaine demonstrated the highest incorporation rate (ICR) into hair, with a staggering 3600-fold difference compared to THCA, which had the lowest ICR. The study evaluated 20 drugs, revealing that cocaine had the strongest affinity for melanin, followed by benzphetamine and phencyclidine. A notable correlation of 0.979 was found between ICRs and the combined factors of melanin affinity and lipophilicity. Basic drugs showed higher ICRs than neutral or acidic ones due to their membrane permeability influenced by the pH gradient between blood and hair matrix.
Abstract
To determine the mechanism involved, the incorporation rate (ICR) of drugs into hair was compared to melanin affinity, lipophilicity and membrane p...
Pharmacological profile of ritanserin: A very specific central serotonin S2‐antagonist
Drug Development Research – January 01, 1988
Summary
Ritanserin demonstrates impressive efficacy as a central serotonin S2-antagonist, with an ED50 of just 0.0070 mg/kg in blocking tryptamine-induced cyanosis. It effectively inhibited tryptamine-triggered seizures at 0.037 mg/kg and reduced serotonin-induced skin reactions with doses as low as 0.04 mg/kg. Notably, ritanserin showed minimal interaction with dopamine and other neurotransmitters, maintaining specificity. While its peripheral histamine antagonism was observed, it required significantly higher doses (10 mg/kg) compared to its serotonin activity, highlighting its unique pharmacological profile.
Abstract
Abstract Ritanserin, a novel methylenepiperidine derivative, was studied in a wide range of common pharmacological tests mainly in rats. The lowest...
Psychedelics and substance use disorder treatment.
International review of neurobiology – January 01, 2025
Summary
Remarkably, certain **hallucinogens** show promise in treating **addiction**. Research indicates **psychedelics** like **LSD**, **psilocybin**, and **ayahuasca** can help individuals with **alcohol use disorder** reduce drinking and achieve abstinence. Promising initial findings also emerge for **tobacco use disorder** and opioid **substance use disorders**. These compounds may work by improving brain function and fostering personal insights, offering a new path for recovery.
Abstract
The current chapter presents the literature evaluating the effects of classic psychedelic treatments on five substance use disorders: alcohol, toba...
Might Microdosing Psychedelics Be Safe and Beneficial? An Initial Exploration.
Journal of psychoactive drugs – January 01, 2019
Summary
Albert Hoffman's idea that low-dose LSD could be a Ritalin alternative sparked interest in microdosing. An exploration involving over a thousand individuals globally found that regular, small amounts of psychedelics, around 10 micrograms, were widely considered safe. Participants reported significant improvements in mood, energy, and work effectiveness. Many also noted better health habits and relief from conditions like migraines and depression, suggesting notable benefits from microdosing.
Abstract
Albert Hoffman suggested that low doses of LSD might be an appropriate alternative to Ritalin. Following this possibility, a systematic exploration...
Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT2A receptor agonists.
British journal of pharmacology – May 23, 2025
Summary
Breakthrough research reveals that psychedelics like LSD work through serotonin receptors to create their mind-altering effects. Scientists discovered a new class of compounds that target the same brain pathways but don't cause hallucinations, potentially offering antidepressant benefits without the intense psychedelic experience. This finding could revolutionize mental health treatment by harnessing therapeutic effects while minimizing disorienting side effects.
Abstract
Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture ...
Sporadic use of classic psychedelics and neuropsychological performance: A cross-sectional analysis.
Progress in neuro-psychopharmacology & biological psychiatry – April 02, 2025
Summary
People who occasionally use psychedelics like psilocybin and LSD may experience enhanced cognitive flexibility and problem-solving abilities. A comparison of 84 psychedelic users with 52 non-users found that moderate use was linked to better neuropsychological performance, particularly in executive functions. Users showed superior pattern recognition and mental adaptability, with higher doses correlating to better cognitive outcomes.
Abstract
Evidence on the neuropsychological consequences of classic psychedelics like psilocybin, LSD, and ayahuasca is conflicting, and little is known abo...
Psychedelics and autobiographical memory - six open questions.
Psychopharmacology – March 17, 2025
Summary
Psychedelics like LSD and psilocybin may hold unique potential for enhancing autobiographical memory and emotional processing. Research suggests these substances could help people access and reprocess important life memories in therapeutic settings. Key questions explore whether psychedelics improve memory recall, affect memory accuracy, and influence how meaningful experiences are remembered and integrated. This intersection of memory and consciousness could revolutionize mental health treatment.
Abstract
Since the earliest LSD research, psychedelics have been claimed to enhance autobiographical memory. Revisiting and processing autobiographical memo...
Lifetime classic psychedelic use and headaches: A cross-sectional study.
Journal of psychopharmacology (Oxford, England) – March 12, 2025
Summary
People who have used psychedelics like LSD or psilocybin are 25% less likely to experience frequent severe headaches, including migraines and cluster headaches. Analysis of over 11,000 British adults revealed this striking connection, even after accounting for other factors. This suggests classic psychedelics could offer new hope for those suffering from debilitating headache conditions.
Abstract
Migraine and cluster headache are two primary headache disorders for which conventional treatments are limited. Classic psychedelic substances such...
Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders.
Pharmaceuticals (Basel, Switzerland) – November 05, 2024
Summary
Breakthrough treatments for addiction are emerging from an unexpected source: psychedelics. Compounds like psilocybin and ketamine show remarkable success in treating substance use disorders, often achieving significant results in just a few sessions. Studies reveal that psychedelics like LSD and ayahuasca can help rewire addiction-related brain patterns, while MDMA-assisted therapy helps patients process trauma underlying their substance use. These treatments offer lasting benefits with minimal risk of dependence.
Abstract
Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (...
Stutterers' experiences on classic psychedelics: A preliminary self-report study.
Journal of fluency disorders – September 01, 2024
Summary
Online discussions reveal promising connections between psychedelics and stuttering relief. Analysis of Reddit posts shows 74% of people who stutter reported reduced symptoms after using psilocybin or LSD. The qualitative study examined 114 self-reported experiences, finding improvements in speech fluency, social anxiety, and emotional well-being among most users.
Abstract
Stuttering poses challenges to social, occupational, and educational aspects of life. Traditional behavioral therapies can be helpful but effects a...
Potential Serotonin 5-HT2A Receptor Agonist of Psychoactive Components of Silene undulata Aiton: LC-MS/MS, ADMET, and Molecular Docking Studies.
Current pharmaceutical biotechnology – January 01, 2025
Summary
African dream herb Silene undulata contains compounds similar to LSD in their interaction with brain receptors. Chemical profiling revealed 51 active compounds, including β-carboline alkaloids. Advanced molecular docking shows these substances bind to serotonin receptors nearly as strongly as LSD, explaining the plant's traditional use in inducing vivid dreams and altered states of consciousness.
Abstract
Silene undulata is historically used for inducing vivid and prophetic lucid dreams, but limited information exists on its phytochemical composition...
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie – December 31, 2023
Summary
Groundbreaking research reveals how psychedelics like psilocybin, LSD, and ayahuasca affect human biology at the molecular level. Scientists tracked how these compounds are processed in the body and mapped their effects on cellular metabolism. While we understand how these substances break down, their broader impact on the body's metabolic systems offers promising insights for mental health treatments.
Abstract
Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attentio...
Functional imaging studies of acute administration of classic psychedelics, ketamine, and MDMA: Methodological limitations and convergent results.
Neuroscience and biobehavioral reviews – November 01, 2023
Summary
Brain scans reveal that psychedelics like psilocybin and LSD consistently alter connectivity between sensory and cognitive brain regions. Using functional magnetic resonance imaging (FMRI), researchers analyzed 91 studies examining how ketamine, MDMA, and other psychedelics affect brain function. Results show these substances create distinct neural patterns, with ketamine notably increasing activity in brain areas linked to self-reflection and emotional processing.
Abstract
Functional magnetic resonance imaging (fMRI) is increasingly used to non-invasively study the acute impact of psychedelics on the human brain. Whil...
Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics.
Neurotrauma reports – January 01, 2023
Summary
People with spinal cord injuries experience unique reactions to psychedelics like psilocybin and LSD, marked by intense muscle spasms and sweating. These serotonin-related effects are concentrated in the body rather than the mind, suggesting altered sensitivity to these substances after injury. While patients return to baseline, these physical responses can diminish the therapeutic benefits.
Abstract
Psychedelic-assisted therapy (PAT) may treat various mental health conditions. Despite its promising therapeutic signal across mental health outcom...
Human neuroimaging: fMRI.
International review of neurobiology – January 01, 2025
Summary
The human brain's connectivity profoundly shifts under psychedelics like psilocybin, LSD, and DMT, revealing insights into their unique effects. Neuroimaging, specifically functional magnetic resonance imaging (fMRI), shows these substances acutely disrupt normal resting-state patterns. This neuropsychopharmacology research suggests these fMRI-observed changes are closely linked to both the characteristic subjective experiences and positive long-term emotional impacts. This deepens our understanding of psychedelics and aids in developing new treatments.
Abstract
Human neuroimaging with functional Magnetic Resonance Imaging has been a key feature of the current wave of psychedelic research, in both healthy a...
Persons With Spinal Cord Injury Report Peripherally Dominant Serotonin-Like Syndrome After Use of Serotonergic Psychedelics
Neurotrauma Reports – January 26, 2024
Summary
Many with spinal cord injuries are exploring psychedelics like psilocybin and LSD. A key insight reveals they often experience intense muscle spasms and other sensitivities, suggesting a unique, peripherally dominant serotonin-like reaction. Understanding this phenomenon is vital for developing protocols to safely harness the therapeutic potential of these compounds, including MDMA, for this population.
Abstract
Psychedelic-assisted therapy (PAT) may treat various mental health conditions. Despite its promising therapeutic signal across mental health outcom...
Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review.
Asian journal of psychiatry – June 26, 2025
Summary
When hallucinogens like LSD or psilocybin induce psychosis, prompt treatment is crucial. A review of cases found second-generation antipsychotics, such as Risperidone, highly effective in resolving psychosis. These performed significantly better than first-generation antipsychotics like Haloperidol, offering positive outcomes for patients experiencing this challenging condition.
Abstract
Psychedelics are increasingly used in the general population, yet they are associated with increased risk of psychosis in a minority of users that ...
The potential of psychedelic medicine - A personal account.
Journal of the neurological sciences – March 15, 2022
Summary
Psychedelics were once explored as therapeutic drugs before criminalization halted research. A toxicologist, living in Haight Ashbury in 1965, studied compounds like LSD, observing their early use for conditions such as addiction. Despite initial promise, negative publicity led to Schedule 1 classification, suppressing exploration of these entheogens and entactogens. This historical account suggests a significant, untapped potential for recovery, highlighting how early therapeutic applications were sidelined.
Abstract
In 1965, I was training in clinical toxicology in the pharmacology department of the University of California San Francisco (UCSF) and living in th...
United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
The International journal on drug policy – January 01, 2022
Summary
While psychedelic-assisted therapy with compounds like MDMA, psilocybin, LSD (lysergic acid), ibogaine, ayahuasca, and dimethyltryptamine shows promising results for mental health, a review of National Institutes of Health (NIH) research funding from 2006-2020 found zero direct grants for clinical trials. Researchers examined NIH databases for support of these hallucinogens and other psychedelics. Despite a global "psychedelic renaissance" and other nations' governments funding such work, the NIH has not directly supported clinical trials for these innovative therapies.
Abstract
Medicine is currently experiencing a "psychedelic renaissance", said by many to have commenced in 2006. Since then, clinical trials have consistent...
[Neurotrophic mechanisms of psychedelic therapy].
Biologie aujourd'hui – January 01, 2019
Summary
Therapeutic effects of psychedelics can last long after the drug is gone, suggesting they trigger lasting brain changes. Studies reveal how compounds like LSD and ketamine (kétamine) impact neurotrophic factors such as BDNF. The central idea is that despite different receptor targets, these psychedelics initiate similar beneficial plastic adaptations in the brain's prefrontal cortex. Positive findings indicate these mechanisms could effectively treat conditions like depression (dépression) and addiction, offering new avenues for mental health care.
Abstract
Psychedelic drugs, often referred to as hallucinogens, are quite distinct from other classes of psychotropic drugs. Although the subjective and beh...
Biological Effects and Biodistribution of Bufotenine on Mice.
BioMed research international – January 01, 2018
Summary
A compound, similar to LSD and effective against rabies, was studied for long-term safety in mice. Researchers assessed its impact on behavior, body functions, and tissue distribution after daily doses. Mice showed only mild behavioral changes at higher doses, maintaining normal physiology and no organ damage. Importantly, the lowest effective dose was safe, with no significant central nervous system impact. These positive results highlight its potential as a drug prototype for incurable diseases like rabies.
Abstract
Bufotenine is an alkaloid derived from serotonin, structurally similar to LSD and psilocin. This molecule is able to inhibit the rabies virus infec...
Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil.
Synapse (New York, N.Y.) – August 01, 2009
Summary
Unexpectedly, phencyclidine (PCP), known for other effects, strongly stimulates dopamine D2 receptors in brain tissue. Researchers investigated if PCP and similar substances like LSD and modafinil activate these receptors. Using rat brain samples, they found PCP, hallucinogens, and psychostimulants effectively activate D2 receptors at behaviorally relevant concentrations, a positive discovery that clarifies how these compounds influence brain activity.
Abstract
Although it is commonly stated that phencyclidine is an antagonist at ionotropic glutamate receptors, there has been little measure of its potency ...
Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans
Biomedicine & Pharmacotherapy – December 31, 2023
Summary
Understanding how the body processes psychedelic compounds is vital for unlocking their therapeutic potential. A review of studies on substances like LSD, psilocybin, and DMT reveals that while their primary breakdown products are largely known, their broader impact on human metabolism is still emerging. Integrating advanced metabolomics with drug tracking promises to illuminate the precise molecular interactions behind their positive therapeutic effects, paving the way for novel treatment development.
Abstract
Psychedelics are classical hallucinogen drugs that induce a marked altered state of consciousness. In recent years, there has been renewed attentio...
Acid Brothers: Henry Beecher, Timothy Leary, and the psychedelic of the century.
Perspectives in biology and medicine – January 01, 2016
Summary
Henry Beecher, a titan of research ethics, and Timothy Leary, a counterculture guru, share an unexpected historical link: LSD. Though never meeting, their contrasting Harvard-era approaches to the synthetic hallucinogen proved pivotal. This perspective reveals how Beecher's ethical principles, forged partly in response to Leary's controversial advocacy, became a crucial bellwether. Their indirect struggle significantly advanced the formal scrutiny and guidelines for responsible human experimentation.
Abstract
Henry Knowles Beecher, an icon of human research ethics, and Timothy Francis Leary, a guru of the counterculture, are bound together in history by ...
Psychedelics and psychotherapy in Canada: Humphry Osmond and Aldous Huxley.
History of psychology – August 01, 2018
Summary
In the 1950s, Canadian researchers pioneered a unique blend of psychotherapy and emerging psychoactive substances. Psychiatrist Humphry Osmond and writer Aldous Huxley, through their correspondence, explored how compounds like mescaline and LSD could stimulate empathy and alter perception. Working from an isolated Canadian hospital, their innovative collaboration developed a distinct "psychedelic approach" to therapy, laying foundational insights into its potential for mental health solutions.
Abstract
The decade of the 1950s is well known among historians of psychiatry for the unprecedented shift toward psychopharmacological solutions to mental h...
25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug
BioMed Research International – January 01, 2014
Summary
A dangerous new hallucinogen, 25C-NBOMe, is rapidly emerging online, often disguised as "legal LSD." Researchers systematically reviewed scientific literature and online discussions across 10 languages to understand its nature and risks. Findings reveal it's a potent substance that binds to specific brain receptors, causing effects like hallucinations, dissociation, and anxiety. Alarmingly, it carries a high risk of overdose, with acute toxicities and fatalities reported. This easily accessible, low-cost drug poses significant harm, underscoring the vital need to inform health professionals about its dangers.
Abstract
Introduction. The use of novel psychoactive substances (NPSs) has rapidly increased as well as their online availability. The aim of this paper is ...
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function.
Pharmacology & therapeutics – May 01, 2019
Summary
Classic psychedelics like LSD and psilocybin, once overlooked, are proving to be powerful therapeutic agents. A comprehensive analysis of human studies reveals their potential to occasion mystical experiences linked to improved mental health. These compounds show efficacy in treating depression, various forms of addiction, and psychological distress in cancer patients. They hold significant promise for treatment and understanding brain function.
Abstract
The purpose of this paper is to provide an integrative review and offer novel insights regarding human research with classic psychedelics (classic ...
Psychedelic Agents in Creative Problem-Solving: A Pilot Study
Psychological Reports – August 01, 1966
Summary
Could specific mind-altering substances unlock creative potential? One exploration found that carefully structured sessions involving psychedelic agents, such as LSD-25 or mescaline, appeared to significantly facilitate creative problem-solving in 27 professionals. Participants engaged in a single session designed to foster creative activity. Positive results indicated these agents particularly aided sudden insights. Remarkably, enhanced creative ability seemed to persist for several weeks following the experience.
Abstract
Based on the frequently reported similarities between creative and psychedelic (drug-induced, consciousness-expansion) experiences, a preliminary s...
Psilocybin and Psilocin
OpenAlex – March 09, 2000
Summary
Psilocybin mushrooms are notably more popular than LSD among college students, with 15% reporting use compared to just 5% for LSD. These "mind-revealing" mushrooms, containing psilocybin and psilocin, have a long history, used ritualistically by Mexican Native Americans for thousands of years. Modern recreational appeal extends to younger demographics; a California survey found 3.4% of seventh graders and 8.8% of eleventh graders had used them, often cultivated at home from readily available spores.
Abstract
Abstract Psilocybin and psilocin are indolealkylamines present in Central American Psilocybe species of mushrooms and in Panaeolus mushroom species...
Psychedelic Experiential Pharmacology: Pioneering Clinical Explorations with Salvador Roquet (How I Came to All of This: Ketamine, Admixtures and Adjuvants, Don Juan and Carlos Castaneda Too): An Interview with Richard Yensen
International Journal of Transpersonal Studies – July 01, 2014
Summary
Pioneering psychedelic drug studies, utilizing compounds like MDA and LSD, revealed profound potential for experiential learning in psychotherapy. Dr. Yensen, a seasoned psychotherapist, conducted FDA-approved research from 1972-1976, exploring neurotransmitter receptor influence on behavior with diverse patients. His Psychology Ph.D. focused on MDA with neurotic outpatients. Later, under IND 3250 until 2006, he continued LSD research, evolving a non-drug psychoanalysis, Perceptual Affective Therapy, from these natural compound pharmacology insights.
Abstract
Richard Yensen was a research fellow at the Maryland Psychiatric Research Center from 1972 to 1976. He studied psychedelic psychotherapy with Stani...
Classic Psychedelics in Pain Modulation: Mechanisms, Clinical Evidence, and Future Perspectives
ACS Chemical Neuroscience – June 06, 2025
Summary
Millions worldwide suffer chronic pain, often with depression. Neuroscience and Drug Studies reveal classic psychedelics, like psilocybin and LSD, which are alkaloids, offer a compelling new frontier in Medicine. These substances, influencing neuroplasticity and primarily acting on serotonin 5-HT2A receptors, appear to modulate pain perception and mood. Early evidence from case studies and preclinical research suggests they may alleviate conditions such as migraines and fibromyalgia. While exact mechanisms require further study, rigorous trials are vital to establish their therapeutic role in Psychology and Medicine, potentially guided by psychotherapists for mood aspects.
Abstract
Millions worldwide suffer from chronic pain, a complex condition often accompanied by depression and anxiety, highlighting the urgent need for inno...
The Relationships Between Healthcare Access, Gender, and Psychedelics and Their Effects on Distress
Healthcare – May 16, 2025
Summary
Psychedelic use can intensify psychological distress, especially for women with public health care. Analyzing data from 484,732 individuals reveals private health insurance links to lower distress, while public coverage correlates with higher distress. For women, psilocybin and LSD use reinforced lower distress with private insurance but significantly heightened distress with public health care. This behavior suggests psychedelics interact with existing healthcare access, failing to mitigate structural inequalities in clinical psychology and potentially worsening outcomes.
Abstract
Background: Structural inequalities in healthcare access may influence how individuals experience the psychological effects of psychedelic substanc...
The effect of psychedelic microdosing on animal behavior: A review with recommendations for the field
Neuroscience & Biobehavioral Reviews – May 09, 2025
Summary
Contrary to popular belief in human psychology, psychedelic microdosing showed minimal behavioral changes in animals. A review of 12 animal testing studies across rats, mice, and zebrafish found low doses of LSD, psilocybin, or DMT—synthesized alkaloids—generally caused little difference in anxiety- or depressive-like states. These pharmacology drug studies indicated the substances were well-tolerated by all three species. While brain chemistry, including nicotinic acetylcholine receptors, may be subtly affected, widespread benefits were not observed.
Abstract
Microdosing, the repeated use of psychedelic substances at low doses, is growing in popularity among recreational consumers. While this practice is...
Is there a place for psychedelics in sports practice?
Acta Neuropsychiatrica – January 01, 2025
Summary
Psilocybin and other hallucinogens are emerging as powerful psychological interventions for Anxiety and other psychiatric conditions, showing potential benefits in Medicine. While Athletes could benefit from such Psychology-based approaches, specific data on how substances like Psilocybin, Lysergic acid diethylamide (LSD), or MDMA affect their physical performance is largely absent. Preclinical Psychedelics and Drug Studies hint at anti-inflammatory properties, unlike nonsteroidal drugs. Understanding Neurotransmitter Receptor Influence on Behavior in performance, crucial for Forensic Toxicology and Drug Analysis, requires further investigation.
Abstract
Abstract Growing evidence suggests that psychedelic-assisted therapies can alleviate depression, anxiety, posttraumatic stress, and substance use d...
Exploring the potential of psychedelic-assisted psychotherapy for moral injury: A scoping review.
Progress in neuro-psychopharmacology & biological psychiatry – April 02, 2025
Summary
Psychedelic-assisted therapy shows promising results in treating moral injury - psychological trauma from events that violate one's core values. Studies examining MDMA, psilocybin, and LSD combined with psychotherapy reveal significant improvements in self-compassion, forgiveness, and PTSD symptoms. The treatments particularly help those struggling with trauma-related moral conflicts and self-acceptance.
Abstract
This scoping review addresses the need to comprehensively explore the potential of psychedelic-assisted psychotherapy (PAP) to facilitate recovery ...
Psychedelics and Pro-Social Behaviors: A Perspective on Autism Spectrum Disorders
ACS Pharmacology & Translational Science – February 10, 2025
Summary
Autism Spectrum Disorders affect millions globally, presenting significant challenges in social interaction. A compelling perspective in cognitive psychology explores how psychedelics like LSD, psilocybin, and MDMA may positively influence pro-social behaviors. This viewpoint examines their neurotransmitter receptor influence on behavior, suggesting novel drug studies. Understanding these mechanisms, alongside insights from nicotinic acetylcholine receptors, could offer new psychological approaches for individuals with ASD.
Abstract
Autism Spectrum Disorders (ASD) are complex neurodevelopmental conditions characterized by deficits in social interaction, communication, and repet...
Psychedelics and Suicide-Related Outcomes: A Systematic Review
Journal of Clinical Medicine – February 20, 2025
Summary
Suicide accounts for 1.4% of global deaths, urging new Medicine. Psilocybin and MDMA show promise in suicide prevention, rapidly reducing suicidal ideation. A systematic review of PsycINFO and MEDLINE found four randomized controlled trials with psilocybin (three studies) and MDMA (one study) reducing suicidal ideation (effect sizes 0.52–1.25). Non-randomized studies reported psilocybin reducing ideation (OR 0.40–0.75). However, LSD, another hallucinogen, increased suicidal ideation (OR 1.15–2.08). Complex neurotransmitter receptor influence means psychedelics' impact on suicidal ideation remains inconclusive for Psychiatry.
Abstract
Background/Objectives: Suicide accounts for 1.4% of global deaths, and the slow-acting nature of traditional treatments for suicide risk underscore...
Further education in psychedelic-assisted therapy - experiences from Switzerland.
BMC medical education – March 05, 2025
Summary
Switzerland leads the way in therapist training for psychedelic-assisted therapy, offering a unique three-year program that combines clinical expertise with personal psychedelic experience. Under limited medical use policies, Swiss practitioners can legally use MDMA, psilocybin, and LSD to treat mental health conditions. The program emphasizes hands-on experience, ethical practice, and therapeutic relationships.
Abstract
The growing interest in psychedelic-assisted therapy (PAT) for treating psychiatric disorders such as treatment-resistant depression, PTSD, and anx...
Prevalence and Correlates of Lifetime Ecstasy/MDMA Use Among Asian American and Pacific Islander Adult Populations in the United States, 2015–2020
Journal of Psychoactive Drugs – March 03, 2025
Summary
Over 1 in 20 Asian American and Pacific Islander adults (5.1%) have used Ecstasy/MDMA in their lifetime. Women showed 1.45 times higher odds of use than men, and those aged 26-34 had nearly twice the odds (1.99 times) compared to younger adults. Lifetime use of other substances like Cannabis (28.4 times higher odds) and Psychedelics such as LSD (3.82 times) or psilocybin (3.29 times) strongly correlated with MDMA use. These demographic insights are crucial for public health, medicine, and Psychiatry strategies, especially in Forensic Toxicology and Drug Analysis, and Gerontology.
Abstract
Little is known about ecstasy/MDMA use among Asian American and Pacific Islander populations. Research is important because AAPIs face unique cultu...
Down the Rabbit Hole: A Large-Scale Survey of Psychedelic Users’ Patterns of Use and Perceived Effects
Journal of Psychoactive Drugs – January 29, 2025
Summary
A survey of 1,486 US adults (67.1% male) provides crucial insights into the evolving landscape of psychedelics and drug studies. Predominantly, people use MDMA and LSD recreationally, often orally. While acute effects like hallucinations and positive mood are common, residual headaches also occur. This psychology research offers a valuable scale for understanding public experiences with these chemical synthesis alkaloids. Deciphering this complex data helps us navigate the rabbit hole of diverse academic research themes surrounding psychedelics.
Abstract
The ever-changing landscape surrounding legality and accessibility of psychedelics and their increasing popularity make it imperative to better und...
Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management.
Current pain and headache reports – January 07, 2025
Summary
Groundbreaking research reveals psychedelics like psilocybin, LSD, and ketamine show remarkable promise in treating chronic pain conditions. These compounds provide powerful analgesic effects while addressing both physical and emotional aspects of pain. Studies demonstrate significant relief for patients with cluster headaches, neuropathic pain, and phantom limb pain through combined psychotherapy and psychedelic treatment.
Abstract
Chronic pain affects approximately 1.5 billion people worldwide, representing the leading cause of disability and a significant financial burden on...